BPC-157 Sourcing Vocabulary and Catalogue Query Orthography: A Research Review of Gastric Pentadecapeptide Identity, Vendor-Token Taxonomy and the Resolution of "bc157 peptides", "bp517" and "bpc 157 injection kit" Labels

By the Peptide Insider Research Desk · October 12 2026 · For research reference only — not for human or veterinary use.

Catalogue searches for bc157 peptides, bp517, peptide 157 and 500 and bpc 157 injection kit converge on a single molecular identity: BPC-157 (Body Protection Compound-157, CAS 137525-51-0, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW 1419.53 Da) [1]. Procurement queries (bpc 157 sources, where to buy peptide bpc 157, research chem bpc 157) reflect sourcing intent, while vendor tokens (bpc 157 amino asylum, blue sky peptide bpc 157, skye peptides bpc 157, farmakeio bpc 157, instamed bpc 157, bpc 157 transcend, amino usa bpc 157, bpc 157 modern aminos, integrity research bpc-157, pure encapsulations bpc 157, bpc-157 peptide science, peptide sciences bpc157, bpc-157 peptide sciences) append trade names this review does not assess. The query bpc 157 pea 500 conflates BPC-157 with PEA and TB-500, reviewed separately on this site.

Key Facts at a Glance

• BPC-157 is a 15-amino-acid gastric juice fragment stable in human gastric fluid for up to 24 hours [1,4].
• The VEGFR2-Akt-eNOS axis is the most consistently reported mediator of its pro-angiogenic activity in rodent models [2,5].
• Preclinical studies report accelerated tendon outgrowth and ligament tensile strength in rat models [6,7].
• A 2022 PK study characterised BPC-157 distribution, metabolism and excretion in rats after IV administration [8].
• No Phase III human trial has been completed as of 2026; all efficacy data are preclinical [1,9].

Catalogue Query Orthography and Vendor-Token Taxonomy

The table below classifies 21 catalogue queries by transcription mechanism and RUO scope status.

All 21 queries resolve to the same pentadecapeptide. "Declined-vendor-specific" means the query is acknowledged but the vendor is not assessed or endorsed. Researchers should independently verify CoA purity, HPLC and MS documentation.

Mechanism of Action: VEGFR2-Akt-eNOS Axis and Pleiotropic Signalling

Despite decades of preclinical investigation, no dedicated receptor for BPC-157 has been identified [1,3]. The peptide's pharmacological profile is instead characterised by convergent modulation of multiple intracellular signalling cascades.

Angiogenesis and Vascular Repair

Hsieh et al. (2017) demonstrated in a rat ischaemic hind-limb model that BPC-157 promoted VEGFR2 internalisation and Akt-eNOS cascade activation, increasing endothelial NO production and capillary density [2]. The Src-Caveolin-1-eNOS axis further modulates vascular tone; when NO synthesis is pharmacologically blocked (L-NAME), pro-angiogenic effects are attenuated, confirming NO dependence [5,10].

FAK-Paxillin and Cellular Migration

BPC-157 activates the FAK-paxillin cascade governing fibroblast attachment to extracellular matrix, facilitating repair-cell recruitment in rodent injury models [3,6]. Chang et al. (2011) showed BPC-157-treated rat Achilles tendon explants exhibited greater outgrowth, cell survival and migration distance, correlating with FAK phosphorylation [6].

Growth Hormone Receptor Upregulation

BPC-157 upregulates GHR expression in tendon fibroblasts, potentially sensitising cells to circulating GH and augmenting collagen synthesis [3,7]. Cerovecki et al. (2010) reported improved ligament tensile strength and collagen organisation in a rat MCL transection model [7].

Preclinical Evidence Table

Gastric Stability and Formulation Context

The query bpc 157 injection kit reflects researcher interest in formulation ancillaries—lyophilised powder, bacteriostatic water, syringes and sterile vials. BPC-157's three consecutive proline residues (Pro³-Pro⁴-Pro⁵) confer pepsin and trypsin resistance, permitting the intact peptide to survive in human gastric juice for up to 24 hours in vitro [1,4]. This stability derives from the polyproline II helix that resists endopeptidase access [4]. BPC-157 is typically supplied as lyophilised powder requiring reconstitution with bacteriostatic water (0.9% benzyl alcohol) and storage at 2–8 °C [4,9]. The query pure encapsulations bpc 157 references an oral capsule format; oral bioavailability in humans has not been established in peer-reviewed pharmacokinetic studies [4,8].

The "Peptide 157 and 500" Blend Query

The query peptide 157 and 500 uses numeric shorthand for a BPC-157 and TB-500 (Thymosin Beta-4 fragment, MW 904.02 Da) combination. BPC-157 acts via VEGFR2/eNOS-mediated angiogenesis; TB-500's actin-sequestering domain promotes cell migration via G-actin polymerisation dynamics [1,12]. Biçer et al. (2026) evaluated co-administration in a rat Achilles tendon model, reporting improved histopathological scores and biomechanical strength versus either peptide alone [12]. Blend queries are catalogued in the dedicated BPC-157 and TB-500 Blend Nomenclature companion review on this site.

Limitations of the Current Evidence Base

The BPC-157 evidence base carries several constraints: the majority of data originate from a single research group (Sikiric et al., University of Zagreb), no Phase III human trial has been completed as of October 2026, no dedicated receptor has been identified, and theoretical oncology concerns regarding VEGFR2 upregulation remain unevaluated in tumour models [1,3,9].

Frequently Asked Questions

What does "bc157 peptides" refer to?

Bc157 peptides is a prefix-truncation variant of BPC-157 (CAS 137525-51-0); the "P" omission is a common catalogue transcription artefact [1].

Is "bp517" the same compound as BPC-157?

Yes. Bp517 is a digit-transposition error (157 → 517); both resolve to the same 15-amino-acid pentadecapeptide, MW 1419.53 Da [1,2].

What is a "bpc 157 injection kit"?

A bpc 157 injection kit refers to bundled research ancillaries: lyophilised powder, bacteriostatic water, syringes and vials. No pharmaceutical-grade kit has received regulatory approval [4,9].

What does "peptide 157 and 500" mean?

Peptide 157 and 500 is numeric shorthand for a BPC-157 (1419.53 Da) and TB-500 (904.02 Da) combination, with proposed pathway convergence between VEGFR2 angiogenesis and G-actin dynamics [1,12].

Where can researchers source BPC-157 for laboratory use?

Researchers should verify CoA documentation: HPLC purity ≥98%, ESI-MS confirming the 1419.53 Da molecular ion, and endotoxin testing. See the sourcing section below.

Where to Source BPC-157 for Research

BPC-157 lyophilisate is catalogued by multiple research-peptide suppliers. Researchers may consult Short Chain Aminos for current catalogue availability and CoA documentation. Additional sources include BioPep, which maintains peptide identity and purity records, Catalyst Research for bulk research-grade formats, and Apex Research Services for ancillary reconstitution supplies. No single vendor is assessed or endorsed by this review; researchers should independently verify CoA purity (≥98% HPLC), ESI-MS molecular-ion confirmation and endotoxin documentation before procurement.

Works Cited

1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550.
2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966.
3. Sikiric P, Rucman R, Turkovic B, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide. Pharmaceuticals (Basel). 2025;18(8):1155. PMID: 41155565.
4. Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Perspectives. Pharmaceutics. 2026;18(2):198. PMID: 42198317.
5. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key. Pharmaceuticals (Basel). 2025;18(5):573. PMID: 40573323.
6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672.
7. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319.
8. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157. Front Pharmacol. 2022;13:1060539. PMID: 36588717.
9. Moiz A, et al. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med. 2026;123(2):111-117. PMID: 42757290.
10. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel). 2023;16(7):992. PMID: 37242459.
11. Jung YH, et al. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. J Dent Anesth Pain Med. 2022;22(2):97-105. PMID: 35449779.
12. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(1):42-50. PMID: 42542926.
13. Vukusic D, et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol. 2024;75(1):38583442. PMID: 38583442.
14. Vukoja I, et al. Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation. J Physiol Pharmacol. 2026;77(1). PMID: 42533460.
15. Jelińska J, et al. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. Int J Mol Sci. 2026;27(3):278. PMID: 42278509.

This article is strictly for research reference; it does not constitute medical advice. BPC-157 is an investigational compound not approved for human or veterinary use. No vendor mentioned in catalogue search logs is assessed or endorsed.